文献速递心脏核医学肿瘤 PET/CT

铷-82 PET检测淋巴瘤患者多柔比星急性心脏效应

Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients.
PubMed 文献 · J Nucl Cardiol · 2018-10-08

研究纳入70例计划接受多柔比星为基础治疗的淋巴瘤患者,在化疗前和首次多柔比星暴露后不久行82Rb PET静息和腺苷负荷心肌灌注显像。54例完整数据患者首次暴露后MPR显著降低(2.69 vs 2.51,P=.03),负荷灌注非显著下降(3.18 vs 3.02 ml/g/min,P=.08),静息灌注无变化。结论认为MPR降低可能代表多柔比星早期心脏毒性标志。

要点

  • 54例完整数据患者首次多柔比星暴露后MPR显著降低(2.69 vs 2.51,P=.03)。
  • 负荷灌注非显著下降(3.18 vs 3.02 ml/g/min,P=.08),静息灌注无变化。
  • 13例患者存在低心脏毒性阈值,其年龄显著更高,其余特征与其余人群相似。

核心结论

  • 淋巴瘤患者首次多柔比星暴露后MPR降低可能代表多柔比星诱导的心脏毒性早期标志。
  • 急性多柔比星诱导的MPR变化的预后价值尚待研究。

研究设计与样本

  • 研究纳入70例计划接受多柔比星为基础治疗的淋巴瘤患者。
  • 在化疗前和首次多柔比星暴露后不久行82Rb PET静息和腺苷负荷心肌灌注显像评估心脏毒性。
  • MPR下降>20%的患者被定义为具有低心脏毒性阈值。

主要发现

  • 54例完整数据患者中,MPR在首次多柔比星暴露后显著降低(2.69 vs 2.51,P=.03)。
  • 负荷灌注出现非显著下降(3.18 vs 3.02 ml/g/min,P=.08),静息心肌灌注无变化。
  • 13例患者具有低心脏毒性阈值,这些患者年龄显著更高,其余方面与研究人群其余部分相似。

关键数值与推荐

  • MPR下降>20%定义为低心脏毒性阈值。
  • MPR在首次多柔比星暴露后显著降低(2.69 vs 2.51,P=.03)。
  • 负荷灌注非显著下降(3.18 vs 3.02 ml/g/min,P=.08)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Doxorubicin is a cornerstone in lymphoma treatment, but is limited by dose-dependent cardiotoxicity. Rubidium-82 positron emission tomography (82Rb PET) assesses coronary microvascular function through absolute quantification of myocardial perfusion and myocardial perfusion reserve (MPR). Doxorubicin-induced microvascular injury represents a potential early marker of cardiotoxicity. METHODS AND RESULTS: We included 70 lymphoma patients scheduled for doxorubicin-based treatment. Cardiotoxicity was evaluated with 82Rb PET myocardial perfusion imaging during rest and adenosine stress before chemotherapy and shortly after the first doxorubicin exposure. Patients with a MPR decline > 20% were defined as having a low threshold for cardiotoxicity. In the 54 patients with complete data sets, MPR was significantly lower after the initial doxorubicin exposure (2.69 vs 2.51, P = .03). We registered a non-significant decline in stress perfusion (3.18 vs 3.02 ml/g/min, P = .08), but no change in resting myocardial perfusion. There were 13 patients with a low cardiotoxic threshold. These patients had a significantly higher age, but were otherwise similar to the remaining part of the study population. CONCLUSION: Decreases in MPR after initial doxorubicin exposure in lymphoma patients may represent an early marker of doxorubicin-induced cardiotoxicity. The prognostic value of acute doxorubicin-induced changes in MPR remains to be investigated.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Laursen AH, Elming MB, Ripa RS, et al. Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients. J Nucl Cardiol. 2018. PMID: 30298372. doi:10.1007/s12350-018-1458-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。